中工國際(002051.SZ)與中國國際醫藥衞生簽訂戰略合作協議
格隆匯5月15日丨中工國際(002051.SZ)公佈,近日,公司與中國國際醫藥衞生有限公司(以下簡稱“國藥國際”)簽訂了《戰略合作協議》。
本協議旨在搭建戰略合作框架,雙方在合作框架內發揮各自優勢,相互配合,共同發展。中工國際依託快捷高效的海外網絡佈局,充分發揮醫療康養建築設計領域的專業優勢、專業化的項目管理能力以及多元化的融資能力;國藥國際充分發揮在海外醫療醫藥項目、醫療服務產業、生命健康產業以及免税業務方面的產業優勢,實現合作共贏。
本次簽訂《戰略合作協議》有利於合作雙方利用各自在海外市場的廣泛佈局和差異化營銷渠道,通過“聯合出海”的方式發揮各自核心優勢,共同開拓海外醫療醫藥業務,實現合作共贏。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.